1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Recalls

Q4 Recalls Snapshot: Fewer Devices Recalled By Industry, But Software Troubles Still Abound

 
• By Shawn M. Schmitt

Problems with software were the No. 1 reason for medical device recalls in the fourth quarter of 2020. Also: Recalls fell by a modest 3%, but the number of recalled device units mushroomed 158%. Check out our Q4 recalls infographic.

Q4 Device Recalls

The number of product recalls initiated by manufacturers fell slightly in the fourth quarter of 2020 – but there was an increase in the count of recalled device units. There were 235 corrections and removals in Q4, compared to 242 in Q3 – a modest 3% decrease. Meanwhile, industry recalled 59,314,216 units in Q4, a 158% increase from Q3, when 22,951,964 units were pulled from the market. In its State of the Nation 2021 recalls index, business solutions company Sedgwick points out that industry is still having troubles with software, as it’s once again the top recall cause – as it has been for 18 of the past 19 quarters.

Nancy Pham / Informa Pharma Intelligence

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

FDA Rebukes Four Companies, Including One Overseas, For Procedural Failures

 
• By Brian Bossetta

The US FDA’s device center sent warning letters to three domestic device manufacturers and one German firm for failing to adhere to protocol on several issues.

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Q’Apel Medical Recalls, Discontinues Stroke Therapy System After FDA Warning Letter, Class I Designation

 
• By Brian Bossetta

Q’Apel Medical has pulled its aspiration system for stroke thrombectomy from the market after concerns raised by the US FDA in a February warning letter.

More from Policy & Regulation

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.